How do anti-NGF antibodies compare to existing injectables for pain relief in osteoarthritis?

Anti-NGF antibodies target pain pathways centrally rather than locally, offering systemic relief but carrying joint-safety signals that have delayed regulatory approvals [3]. Viscosupplements remain preferred for localized mechanical symptom management. Read More

What reimbursement models are gaining traction for premium osteoarthritis therapies?

Outcomes-based contracts linking payment to measurable pain-score improvements and arthroplasty deferral timelines are piloting across U.S. and European payers [16]. These models shift financial risk to manufacturers. Read More

How is the Osteoarthritis Market affected by the rise of ambulatory surgical centers?

Ambulatory centers reduce per-procedure costs by 30–40% compared to hospital settings, accelerating injectable adoption [6]. They are expanding the treatable patient base by improving access and convenience. Read More

What role does AI play in osteoarthritis diagnosis and treatment planning?

AI algorithms trained on radiographic data can stage disease severity with specialist-level accuracy, reducing diagnostic delays [13]. Earlier diagnosis expands the pharmaceutical intervention window. Read More

Which Osteoarthritis Market segments present the highest near-term investment returns?

Single-injection hyaluronic acid products combine high gross margins with strong clinical differentiation and growing payer acceptance [9]. Their surgical-deferral value proposition resonates with cost-conscious health systems. Read More

How are biosimilar entrants reshaping competitive dynamics in the Osteoarthritis Market?

Biosimilar NSAIDs and corticosteroid formulations are compressing branded pricing by 15–20% in key markets [7]. Innovators are responding by shifting portfolios toward differentiated biologics. Read More

What procurement strategies should hospital buyers consider for the Osteoarthritis Market?

Group purchasing organization contracts that bundle injectable viscosupplements with extended-release corticosteroids can reduce per-patient costs by 10–15% [6]. Volume-tiered pricing from specialty distributors offers additional savings. Read More

What is the current size of the osteoarthritis market?

The osteoarthritis market reached USD 8.21 billion in 2025 and is projected to reach USD 13.51 billion by 2035. Read More

What is the CAGR of the osteoarthritis market?

The osteoarthritis market is projected to grow at a CAGR of 5.10% during the forecast period 2026–2035. Read More

Which region leads the osteoarthritis market?

North America holds the largest share at 45.6%, while Asia-Pacific is the fastest-growing region at 6.05% CAGR. Read More

Osteoarthritis Therapeutics Market (2026 - 2035)

ID: MRFR/Pharma/1078-HCR

90 Pages

Nidhi Mandole

Last Updated: July 10, 2026

Osteoarthritis Market Research Report By Treatment Type (Medication, Surgery, Therapy), By Diagnosis (Imaging, Joint Fluid Analysis), By Route of Administration (Oral, Topical, Parenteral), By Disease Type (Knee Osteoarthritis, Spine Osteoarthritis, Foot & Ankle Osteoarthritis, Shoulder Osteoarthritis, Hand Osteoarthritis) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Industry Forecast to 2035.

Osteoarthritis Therapeutics Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)5.10%

2025 Market SizeUSD 8.21 Billion

2035 Market SizeUSD 13.51 Billion

Key Players

Pfizer Inc.

Johnson & Johnson

Sanofi S.A.

Bayer AG

Bioventus Inc.

Anika Therapeutics

Trends

Aging Global Population and Expanding Patient Pool
Rising Obesity Rates Across Developed Economies
Shift Toward Injectable and Topical Formulations

Opportunities

Disease-Modifying Osteoarthritis Drug Breakthroughs
Digital Therapeutics and AI-Enabled Remote Monitoring
Emerging Market Penetration in Southeast Asia and Latin America

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Aging Global Population and Expanding Patient Pool | |
  2. 3.1.2 Rising Obesity Rates Across Developed Economies | |
  3. 3.1.3 Shift Toward Injectable and Topical Formulations | |
  4. 3.1.4 Insurance Expansion in Emerging Economies | |
  5. 3.1.5 Hospital Budget Reallocation from Arthroplasty | |
  6. 3.1.6 Digital Health Integration in Chronic Care | |
  7. 3.1.7 Pipeline Disease-Modifying OA Drugs |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Reimbursement Barriers for Advanced Therapeutics | |
  2. 3.2.2 Generic Price Erosion Compressing Revenue per Unit | |
  3. 3.2.3 Regulatory Complexity for Regenerative and Cell-Based Therapies | |
  4. 3.2.4 Evidence Gaps for Disease-Modifying Drugs | |
  5. 3.2.5 Patient Non-Adherence in Chronic Care |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Disease-Modifying Osteoarthritis Drug Breakthroughs | |
  2. 3.3.2 Digital Therapeutics and AI-Enabled Remote Monitoring | |
  3. 3.3.3 Emerging Market Penetration in Southeast Asia and Latin America | |
  4. 3.3.4 Point-of-Care Injection Clinics and Ambulatory Models | |
  5. 3.3.5 Real-World Evidence Platforms for Payer Negotiations |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Osteoarthritis Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Drug Class | |
  1. 5.1.1 NSAIDs | |
  2. 5.1.2 Analgesics | |
  3. 5.1.3 Corticosteroids | |
  4. 5.1.4 Hyaluronic Acid | |
  5. 5.1.5 Others |
2. 5.2 By Anatomy | |
  1. 5.2.1 Knee | |
  2. 5.2.2 Hip | |
  3. 5.2.3 Shoulder | |
  4. 5.2.4 Ankle | |
  5. 5.2.5 Other Anatomies |
3. 5.3 By Distribution Channel | |
  1. 5.3.1 Hospital Pharmacies | |
  2. 5.3.2 Retail Pharmacies | |
  3. 5.3.3 Online Pharmacies |
4. 5.4 By End User | |
  1. 5.4.1 Hospitals | |
  2. 5.4.2 Orthopedic Clinics | |
  3. 5.4.3 Others
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Pfizer Inc. | |
  2. 7.3.2 Johnson & Johnson | |
  3. 7.3.3 Sanofi S.A. | |
  4. 7.3.4 Bayer AG | |
  5. 7.3.5 Bioventus Inc. | |
  6. 7.3.6 Anika Therapeutics | |
  7. 7.3.7 Zimmer Biomet Holdings | |
  8. 7.3.8 Smith & Nephew plc | |
  9. 7.3.9 Fidia Farmaceutici S.p.A. | |
  10. 7.3.10 Ferring Pharmaceuticals | |
  11. 7.3.11 Seikagaku Corporation
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Driven Diagnostics and Precision Treatment Selection |
2. 8.2 Regenerative Medicine Entering Mainstream Clinical Practice |
3. 8.3 Digital Therapeutics and Connected Care Ecosystems |
4. 8.4 Value-Based Contracting and Outcomes-Linked Pricing
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Osteoarthritis Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Osteoarthritis Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Global Osteoarthritis Market – Driver Impact Analysis |
TABLE 4 Global Osteoarthritis Market – Restraint Impact Analysis |
TABLE 5 Global Osteoarthritis Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 6 Global Osteoarthritis Market Size, by Anatomy, 2021–2035 (USD Billion) |
TABLE 7 Global Osteoarthritis Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 8 Global Osteoarthritis Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 9 Global Osteoarthritis Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 10 North America Osteoarthritis Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Europe Osteoarthritis Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 12 Asia-Pacific Osteoarthritis Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 13 South America Osteoarthritis Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 14 Middle East & Africa Osteoarthritis Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 15 North America Osteoarthritis Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 16 North America Osteoarthritis Market Size, by Anatomy, 2021–2035 (USD Billion) |
TABLE 17 North America Osteoarthritis Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 18 North America Osteoarthritis Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 19 Europe Osteoarthritis Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 20 Europe Osteoarthritis Market Size, by Anatomy, 2021–2035 (USD Billion) |
TABLE 21 Europe Osteoarthritis Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 22 Europe Osteoarthritis Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 23 Asia-Pacific Osteoarthritis Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 24 Asia-Pacific Osteoarthritis Market Size, by Anatomy, 2021–2035 (USD Billion) |
TABLE 25 Asia-Pacific Osteoarthritis Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 26 Asia-Pacific Osteoarthritis Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 27 South America Osteoarthritis Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 28 South America Osteoarthritis Market Size, by Anatomy, 2021–2035 (USD Billion) |
TABLE 29 South America Osteoarthritis Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 30 South America Osteoarthritis Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 31 Middle East & Africa Osteoarthritis Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 32 Middle East & Africa Osteoarthritis Market Size, by Anatomy, 2021–2035 (USD Billion) |
TABLE 33 Middle East & Africa Osteoarthritis Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 34 Middle East & Africa Osteoarthritis Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 35 Competitive Benchmarking Matrix – Global Osteoarthritis Market, 2025 |
TABLE 36 Company Profiles – Key Players, Global Osteoarthritis Market |
TABLE 37 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 38 Report Scope & Methodology Summary
13 LIST OF FIGURES |
FIGURE 1 Global Osteoarthritis Market Dynamics Overview |
FIGURE 2 Industry Value Chain Analysis – Osteoarthritis Market |
FIGURE 3 Porter's Five Forces Analysis – Global Osteoarthritis Market |
FIGURE 4 Global Osteoarthritis Market Size Trend (USD Billion), 2021–2035 |
FIGURE 5 Global Osteoarthritis Market Share, by Drug Class (%), 2025 |
FIGURE 6 Global Osteoarthritis Market Share, by Anatomy (%), 2025 |
FIGURE 7 Global Osteoarthritis Market Share, by Distribution Channel (%), 2025 |
FIGURE 8 Global Osteoarthritis Market Share, by End User (%), 2025 |
FIGURE 9 Global Osteoarthritis Market Share, by Region (%), 2025 |
FIGURE 10 North America Osteoarthritis Market Size Trend, 2021–2035 |
FIGURE 11 Europe Osteoarthritis Market Size Trend, 2021–2035 |
FIGURE 12 Asia-Pacific Osteoarthritis Market Size Trend, 2021–2035 |
FIGURE 13 South America Osteoarthritis Market Size Trend, 2021–2035 |
FIGURE 14 Middle East & Africa Osteoarthritis Market Size Trend, 2021–2035 |
FIGURE 15 Competitive Landscape – Market Share Analysis, 2025

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
Drug Class	NSAIDs, Analgesics, Corticosteroids, Hyaluronic Acid, Others	NSAIDs	Hyaluronic Acid
Anatomy	Knee, Hip, Shoulder, Ankle, Other Anatomies	Knee	Shoulder
Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies	Hospital Pharmacies	Online Pharmacies
End User	Hospitals, Orthopedic Clinics, Others	Hospitals	Orthopedic Clinics
Geography	North America, Europe, Asia-Pacific, South America, Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Drug Class

Sub-Segment	Key Trend
NSAIDs	Shift from oral to topical formulations for improved safety profiles
Analgesics	Combination acetaminophen-tramadol protocols for moderate pain management
Corticosteroids	Extended-release intra-articular formulations reducing injection frequency
Hyaluronic Acid	Single-injection cross-linked products replacing multi-dose regimens
Others	Emerging biologics, nutraceuticals, and disease-modifying pipeline agents

NSAIDs remain the largest drug class due to established efficacy and low cost, while hyaluronic acid injectables lead growth as clinical evidence increasingly supports their role in deferring surgical intervention.

By Anatomy

Sub-Segment	Key Trend
Knee	Largest addressable population; highest injectable procedure volumes
Hip	Growing demand for pre-arthroplasty pharmaceutical management
Shoulder	Rising detection through advanced MRI and ultrasound imaging
Ankle	Post-traumatic osteoarthritis driving specialist referrals
Other Anatomies	Hand and spine osteoarthritis gaining clinical attention

Knee disease dominates therapeutic spending across all regions, while shoulder osteoarthritis is emerging as a high-growth segment as improved imaging expands the diagnosed patient pool.

By Distribution Channel

Sub-Segment	Key Trend
Hospital Pharmacies	Institutional procurement of injectable therapies for in-patient and outpatient administration
Retail Pharmacies	Outpatient dispensing of oral NSAIDs and topical analgesics
Online Pharmacies	Chronic medication refill automation and home delivery for elderly patients

Hospital pharmacies lead by revenue share given the clinical administration requirements of injectable products, while online channels are growing fastest as digital pharmacy platforms improve access for chronic disease management.

By End User

Sub-Segment	Key Trend
Hospitals	Comprehensive diagnostic, pharmaceutical, and surgical osteoarthritis management
Orthopedic Clinics	Ambulatory injection procedures shifting away from hospital settings
Others	Primary care physicians, rehabilitation centers, and physiotherapy clinics

Hospitals capture the largest share of end-user spending, but orthopedic clinics represent the fastest-growing segment as ambulatory care models reduce procedural costs and improve patient access.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”